Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -62.57M | -56.14M |
| Total Depreciation and Amortization | -- | -- | -- | 42.00K | 30.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | 17.69M | 16.85M |
| Change in Net Operating Assets | -- | -- | -- | -2.06M | -7.43M |
| Cash from Operations | -- | -- | -- | -46.90M | -46.69M |
| Capital Expenditure | -- | -- | -- | -601.50K | -590.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 93.00K | 62.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -508.50K | -528.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 954.50K | 253.50K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 234.52M | 253.43M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -298.00K | -- |
| Cash from Financing | -- | -- | -- | 235.18M | 253.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 187.77M | 206.47M |